Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Given Consensus Rating of “Buy” by Analysts

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) has earned an average rating of “Buy” from the seven ratings firms that are presently covering the stock, MarketBeat.com reports. Seven investment analysts have rated the stock with a buy recommendation. The average 1 year price objective among brokers that have updated their coverage on the stock in the last year is $64.86.

ARCT has been the topic of a number of recent analyst reports. William Blair reaffirmed an “outperform” rating on shares of Arcturus Therapeutics in a report on Thursday, May 23rd. Canaccord Genuity Group dropped their price objective on shares of Arcturus Therapeutics from $87.00 to $86.00 and set a “buy” rating on the stock in a report on Friday, May 10th. Finally, HC Wainwright reissued a “buy” rating and issued a $60.00 price objective on shares of Arcturus Therapeutics in a report on Tuesday.

Arcturus Therapeutics Stock Down 9.2 %

Shares of NASDAQ ARCT opened at $21.48 on Wednesday. The firm’s 50-day moving average price is $29.99 and its 200-day moving average price is $32.57. The company has a market cap of $578.46 million, a PE ratio of -5.49 and a beta of 2.65. Arcturus Therapeutics has a 52-week low of $17.52 and a 52-week high of $45.00.

Arcturus Therapeutics (NASDAQ:ARCT) last announced its quarterly earnings results on Wednesday, May 8th. The biotechnology company reported ($1.00) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.17) by $0.17. The firm had revenue of $38.01 million for the quarter, compared to the consensus estimate of $22.12 million. Arcturus Therapeutics had a negative net margin of 81.59% and a negative return on equity of 37.61%. As a group, equities research analysts anticipate that Arcturus Therapeutics will post -4.39 EPS for the current fiscal year.

Insider Buying and Selling

In other Arcturus Therapeutics news, COO Pad Chivukula sold 26,000 shares of the firm’s stock in a transaction that occurred on Monday, June 3rd. The shares were sold at an average price of $40.01, for a total transaction of $1,040,260.00. Following the sale, the chief operating officer now owns 447,448 shares in the company, valued at approximately $17,902,394.48. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 13.80% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Arcturus Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in ARCT. Charles Schwab Investment Management Inc. raised its stake in Arcturus Therapeutics by 3.0% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 183,941 shares of the biotechnology company’s stock worth $4,700,000 after acquiring an additional 5,435 shares during the period. FMR LLC raised its stake in Arcturus Therapeutics by 8.6% during the 3rd quarter. FMR LLC now owns 940,281 shares of the biotechnology company’s stock worth $24,024,000 after acquiring an additional 74,081 shares during the period. Trexquant Investment LP raised its position in shares of Arcturus Therapeutics by 49.7% during the third quarter. Trexquant Investment LP now owns 51,871 shares of the biotechnology company’s stock valued at $1,325,000 after buying an additional 17,230 shares during the last quarter. Qube Research & Technologies Ltd raised its position in shares of Arcturus Therapeutics by 86.6% during the third quarter. Qube Research & Technologies Ltd now owns 155,456 shares of the biotechnology company’s stock valued at $3,972,000 after buying an additional 72,143 shares during the last quarter. Finally, Schonfeld Strategic Advisors LLC bought a new stake in shares of Arcturus Therapeutics during the third quarter valued at approximately $2,738,000. Institutional investors own 94.54% of the company’s stock.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.